

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis ID6351

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

<p>Multiple sclerosis affects roughly three times more women than men. Accordingly, additional considerations may be needed for those considering pregnancy, and pregnant or breast-feeding women. Being male or older are risk factors for non-relapsing secondary progressive multiple sclerosis.</p> <p>Deprivation negatively impacts access to disease modifying therapies.</p> <p>Access and take-up of disease modifying therapies may differ across ethnicities. Black and ethnic minority people are twice as likely to transition to secondary progressive multiple sclerosis, so the present lack of treatment options may disproportionately impact them.</p> <p>The nature and severity of the condition may constitute a disability. It may be challenging for those who have higher levels of disability and/or live far from specialist centres to attend initiation and monitoring visits.</p>

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

The prevalence of a condition cannot be accounted for in a technology appraisal.
--

The committee should consider the benefits of tolebrutinib, including the once-daily oral formulation, compared with other available treatments for the groups highlighted in question 1.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

Stakeholders have been added following suggestions from consultation, but they were not added specifically for potential equalities issues.

Approved by Associate Director: Emily Crowe...

Date: 04/08/2025